NASDAQ Congratulates GATC on the Launch of Its Derisq AI Report with Times Square Display

Derisq could revolutionize decision-making for public biotech companies by predicting drug candidate safety, efficacy and non-obvious side effects prior to deploying development capital.

New York, NY—October 9, 2025—GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, was featured Wednesday, October 8, on Nasdaq’s iconic Times Square display supporting GATC’s industry rollout of Derisq™, the first AI report to derisk investment decisions for biotech companies and their investors.

“About 98% of public biotechs in the U.S. are listed on Nasdaq,” noted GATC President, Dr. Rahul Gupta. “Positioned at the nexus of technology and the capital markets, Nasdaq understands the impact a product like GATC Health’s Derisq AI report could make on its biotech members and the investment community. Quantifying risk prior to deploying capital is at the heart of investing, and we’re proud to have our Derisq product recognized by Nasdaq with this Times Square display.”

Nasdaq commemorated the launch of Derisq at Fierce Biotech Week with a 10,000 square foot illuminated display in Times Square, NYC. This powerful visual is emblematic of our excitement in working with biotech industry members, both public and private. We encourage those who might be interested in learning more to visit Derisq’s website and schedule a consultation with our team.

About GATC Health Corp

GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health's risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating novel intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.